

miglustat (Zavesca)

(No: 133/04)

Actelion

Summary of Advice

13 December 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The advice is summarised as follows:

Advice: following a full submission.

Miglustat is accepted for use within NHS Scotland for the treatment of mild to moderate type 1 Gaucher disease in patients for whom enzyme replacement therapy is unsuitable.

Miglustat should only be initiated by physicians experienced in the management of Gaucher's disease.

Professor David H Lawson
Chairman